Intraocular Pressure Changes: an Important Determinant of the Biocompatibility of Intravitreous Implants

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Dec 24

PMID 22194895

Citations 4

Authors

Ling Zou

Ashwin Nair

Hong Weng

Yi-Ting Tsai

Zhibing Hu

Liping Tang

Affiliations

Soon will be listed here.

Abstract

Background: In recent years, research efforts exploring the possibility of using biomaterial nanoparticles for intravitreous drug delivery has increased significantly. However, little is known about the effect of material properties on intravitreous tissue responses.

Principal Findings: To find the answer, nanoparticles made of hyaluronic acid (HA), poly (l-lactic acid) (PLLA), polystyrene (PS), and Poly N-isopropyl acrylamide (PNIPAM) were tested using intravitreous rabbit implantation model. Shortly after implantation, we found that most of the implants accumulated in the trabecular meshwork area followed by clearance from the vitreous. Interestingly, substantial reduction of intraocular pressure (IOP) was observed in eyes implanted with particles made of PS, PNIPAM and PLLA, but not HA nanoparticles and buffered salt solution control. On the other hand, based on histology, we found that the particle implantation had no influence on cornea, iris and even retina. Surprisingly, substantial CD11b+ inflammatory cells were found to accumulate in the trabecular meshwork area in some animals. In addition, there was a good relationship between recruited CD11b+ cells and IOP reduction.

Conclusions: Overall, the results reveal the potential influence of nanoparticle material properties on IOP reduction and inflammatory responses in trabecular meshwork. Such interactions may be critical for the development of future ocular nanodevices with improved safety and perhaps efficacy.

Citing Articles

Emerging trends in long-acting sustained drug delivery for glaucoma management.

So Y, Mishra D, Gite S, Sonawane R, Waite D, Shaikh R Drug Deliv Transl Res. 2025; .

PMID: 39786666 DOI: 10.1007/s13346-024-01779-4.

A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma.

Xie L, Yue W, Ibrahim K, Shen J Pharmaceutics. 2021; 13(9).

PMID: 34575410 PMC: 8467666. DOI: 10.3390/pharmaceutics13091335.

Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review.

Cegielska O, Sajkiewicz P Polymers (Basel). 2019; 11(11).

PMID: 31652975 PMC: 6918324. DOI: 10.3390/polym11111742.

Gene transfer to the outflow tract.

Dang Y, Loewen R, Parikh H, Roy P, Loewen N Exp Eye Res. 2016; 158:73-84.

PMID: 27131906 PMC: 5083245. DOI: 10.1016/j.exer.2016.04.023.

Silver and gold nanoparticles exposure to in vitro cultured retina--studies on nanoparticle internalization, apoptosis, oxidative stress, glial- and microglial activity.

Soderstjerna E, Bauer P, Cedervall T, Abdshill H, Johansson F, Englund Johansson U PLoS One. 2014; 9(8):e105359.

PMID: 25144684 PMC: 4140780. DOI: 10.1371/journal.pone.0105359.

References

Ohno S, Ichiishi A, Matsuda H . Hypotensive effect of carteolol on intraocular pressure elevation and secondary glaucoma associated with endogenous uveitis. Ophthalmologica. 1989; 199(1):41-5. DOI: 10.1159/000310013. View

Lloyd A, Faragher R, Denyer S . Ocular biomaterials and implants. Biomaterials. 2001; 22(8):769-85. DOI: 10.1016/s0142-9612(00)00237-4. View

Lai J, Ma D, Cheng H, Sun C, Huang S, Li Y . Ocular biocompatibility of carbodiimide cross-linked hyaluronic acid hydrogels for cell sheet delivery carriers. J Biomater Sci Polym Ed. 2010; 21(3):359-76. DOI: 10.1163/156856209X416980. View

Vega E, Egea M, Valls O, Espina M, Garcia M . Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J Pharm Sci. 2006; 95(11):2393-405. DOI: 10.1002/jps.20685. View

Nair A, Zou L, Bhattacharyya D, Timmons R, Tang L . Species and density of implant surface chemistry affect the extent of foreign body reactions. Langmuir. 2008; 24(5):2015-24. PMC: 3230931. DOI: 10.1021/la7025973. View

Vandervoort J, Ludwig A . Ocular drug delivery: nanomedicine applications. Nanomedicine (Lond). 2007; 2(1):11-21. DOI: 10.2217/17435889.2.1.11. View

Beeley N, Rossi J, Mello-Filho P, Mahmoud M, Fujii G, de Juan Jr E . Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J Biomed Mater Res A. 2005; 73(4):437-44. DOI: 10.1002/jbm.a.30294. View

Padilla De Jesus O, Ihre H, Gagne L, Frechet J, Szoka Jr F . Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem. 2002; 13(3):453-61. DOI: 10.1021/bc010103m. View

Lu J, Wang X, Marin-Muller C, Wang H, Lin P, Yao Q . Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009; 9(4):325-41. PMC: 2701163. DOI: 10.1586/erm.09.15. View

10.

Einmahl S, Ponsart S, Bejjani R, DHermies F, Savoldelli M, Heller J . Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation. J Biomed Mater Res A. 2003; 67(1):44-53. DOI: 10.1002/jbm.a.10597. View

11.

Johnson M, Kass M, Moses R, Grodzki W . Increased corneal thickness simulating elevated intraocular pressure. Arch Ophthalmol. 1978; 96(4):664-5. DOI: 10.1001/archopht.1978.03910050360012. View

12.

Musa F, Srinivasan S, King C, Kamal A . Raised intraocular pressure and orbital inflammation: a rare IgE-mediated allergic reaction to sub-Tenon's hyaluronidase. J Cataract Refract Surg. 2006; 32(1):177-8. DOI: 10.1016/j.jcrs.2005.11.024. View

13.

Fitzpatrick S, Mazumder M, Lasowski F, Fitzpatrick L, Sheardown H . PNIPAAm-grafted-collagen as an injectable, in situ gelling, bioactive cell delivery scaffold. Biomacromolecules. 2010; 11(9):2261-7. DOI: 10.1021/bm100299j. View

14.

Amrite A, Edelhauser H, Singh S, Kompella U . Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis. 2008; 14:150-60. PMC: 2254958. View

15.

Ambati J, Wynne K, Angerame M, Robinson M . Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol. 1999; 83(10):1153-8. PMC: 1722828. DOI: 10.1136/bjo.83.10.1153. View

16.

Choonara Y, Pillay V, Danckwerts M, Carmichael T, du Toit L . A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases. J Pharm Sci. 2009; 99(5):2219-39. DOI: 10.1002/jps.21987. View

17.

Kaur I, Kanwar M . Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002; 28(5):473-93. DOI: 10.1081/ddc-120003445. View

18.

Lu P, Lai J, Tabata Y, Hsiue G . A methodology based on the "anterior chamber of rabbit eyes" model for noninvasively determining the biocompatibility of biomaterials in an immune privileged site. J Biomed Mater Res A. 2007; 86(1):108-16. DOI: 10.1002/jbm.a.31619. View

19.

Stoiber J, Fernandez V, Lamar P, Decker S, Dubovy S, Hitzl W . Trabecular meshwork alteration and intraocular pressure change following pulsed near-infrared laser trabeculoplasty in cats. Ophthalmic Surg Lasers Imaging. 2005; 36(6):471-81. View

20.

Khoobehi B, Stradtmann M, Peyman G, Aly O . Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. Ophthalmic Surg. 1991; 22(3):175-80. View